A Stark Disparity: Epilepsy Mortality and the Pharmacology of Care Gaps
A major population-based analysis in England reveals a critical pharmacoepidemiological challenge: adults with intellectual disability and epilepsy face a significantly higher burden of premature mortality, with epilepsy itself being the primary cause of death in 16.2% of cases. Published in the Journal of Neurology, Neurosurgery & Psychiatry, the study of nearly 10,000 deaths from 2016–2021 found that individuals whose death was attributed to epilepsy died at a median age of 56, six years younger than those who died of other causes. The research identifies systemic risk factors beyond simple drug efficacy, including poor quality of care, service gaps, and a lack of annual health checks—factors that directly impact therapeutic drug monitoring and adherence. Notably, access to multidisciplinary support, particularly psychiatry and speech and language therapy, was found to be protective, highlighting the complex interplay between pharmacotherapy and comprehensive care in managing chronic neurological conditions.
Study Significance: For pharmacologists and clinicians, this study underscores that optimizing pharmacokinetics and pharmacodynamics is insufficient if structural healthcare inequalities prevent consistent drug delivery and monitoring. The findings argue for a pharmacogenomic-informed, personalized medicine approach that is embedded within redesigned, accessible care systems, particularly for vulnerable populations. It shifts the focus from drug development alone to the critical implementation science required to ensure therapeutics reach their intended therapeutic window and improve real-world outcomes.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
